RESULTS OF THE COMBINED GENERAL MEETING OF 28 JUNE 2024
The shareholders approved all the resolutions on which the Board of Directors recommended a favorable vote
Read more
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
News & events
Press release
Press release
PHAXIAM Therapeutics announces the success of its rights issue of €7.8m
Following the subscription period, which closed on June 25, 2024, total demand amounted to approximately 3.9 million shares, representing approximately €7.8 million, i.e. a subscription rate of around 77.1%:
Read morePress release
PHAXIAM Therapeutics launches a rights issue of approximately €10m, which may be increased up to approximately €11.5m if the extension clause is exercised in full, in order to accelerate the implementation of its clinical strategy
Webinar (in French) on June 18, 2024, at 6:00 pm : Register here
Read morePress release
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
Shareholders of PHAXIAM are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company’s registered office at 60 avenue Rockefeller – 69008 Lyon (France).
Read morePress release
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
Webinar (in French) today, May 15, 2024, at 6.00 pm CEST
Read moreNews
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
Read more
Press release
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
Read more
News
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
Read more
Press release
PHAXIAM Therapeutics announces 2023 Full-Year Results and Provides Business Update
Conference call and webcast (English) on Thursday, March 21, 2024 at 9:30am ET / 2:30pm CET
Read morePress release
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
PHAXIAM today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective
Read morePress release
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
Read more
News
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
As of December 31, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €10.5 million (approximately $11.6 million).
Read more